The 2018 Annual ASCO meeting was held in Chicago, IL between June 1 – 5th. The Annual Meeting brings together oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.
Dr. Paul Nghiem presented on the, “Two-year efficacy and safety update from JAVELIN Merkel 200 part A: a registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.”In addition the avelumab study, Dr. Nghiem also presented on the, “Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy.” In these talks, Dr. Nghiem highlights the logistics of each study, their current status, and their findings.
To learn more about these studies from Dr. Nghiem’s presentation, please view the videos posted below.
The authoritative source on Merkel cell carcinoma.
May 20, 2020
- What is a Merkel cell?
- What is Merkel cell carcinoma?
- Symptoms & appearance of Merkel cell carcinoma
- Causes of Merkel cell carcinoma
- Surgical excision
- Mohs micrographic surgery
- Radiation therapy
- Complementary & alternative therapies
- Clinical trials
- Adjuvant Avelumab in Merkel Cell Carcinoma Trial